Intensity Therapeutics, Inc. (INTS)
NASDAQ: INTS · Real-Time Price · USD
7.38
-0.04 (-0.54%)
Mar 13, 2026, 10:12 AM EDT - Market open

Intensity Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Mar '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
1927117---
Market Cap Growth
-43.73%-77.35%----
Enterprise Value
11.8524.14102.85000
Last Close Price
7.3844.00214.25---
PE Ratio
--1.50-6.21---
PB Ratio
2.029.128.93---
P/TBV Ratio
0.948.395.61---
P/FCF Ratio
--1.75-16.31---
P/OCF Ratio
--1.75-16.31---
EV/EBITDA Ratio
--1.46-12.59---
EV/EBIT Ratio
--1.46-12.36---
EV/FCF Ratio
--1.59-14.27---
Debt / Equity Ratio
0.010.040.0100.110.04
Debt / EBITDA Ratio
-0.01-0.01-0.02-0.02-0.04-0.08
Debt / FCF Ratio
-0.01-0.01-0.02-0.03-0.05-0.09
Net Debt / Equity Ratio
-0.96-0.84-1.110.080.495.66
Net Debt / EBITDA Ratio
0.580.151.790.160.541.44
Net Debt / FCF Ratio
0.730.162.030.210.621.64
Quick Ratio
3.111.483.730.191.226.92
Current Ratio
3.601.923.910.211.277.04
Return on Equity (ROE)
-231.48%-202.34%-261.36%400.94%-161.84%-75.07%
Return on Assets (ROA)
-167.53%-150.24%-87.33%-216.55%-104.30%-65.23%
Return on Invested Capital (ROIC)
-3257.10%3476.94%503.88%553.79%1351.85%1528.52%
Return on Capital Employed (ROCE)
-232.85%-202.70%-201.09%423.38%-155.62%-74.95%
Earnings Yield
-62.42%-66.48%-16.10%---
FCF Yield
--57.18%-6.13%---
Buyback Yield / Dilution
-117.66%-10.90%-17.23%---
Updated Nov 6, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q